Jules L Dienstag

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy
    J L Dienstag
    Gastrointestinal Unit, Liver Biliary Pancreas Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Hepatology 30:1082-7. 1999
  2. ncbi request reprint Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Drug Investig 27:35-49. 2007
  3. doi request reprint Hepatitis B virus infection
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital, and Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston 02114, USA
    N Engl J Med 359:1486-500. 2008
  4. ncbi request reprint Durability of serologic response after lamivudine treatment of chronic hepatitis B
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
    Hepatology 37:748-55. 2003
  5. ncbi request reprint Histological outcome during long-term lamivudine therapy
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital, Boston, MA 02114, USA
    Gastroenterology 124:105-17. 2003
  6. ncbi request reprint The role of liver biopsy in chronic hepatitis C
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital, Boston, MA 02114, USA
    Hepatology 36:S152-60. 2002
  7. doi request reprint Benefits and risks of nucleoside analog therapy for hepatitis B
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital and the Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston, MA 02114, USA
    Hepatology 49:S112-21. 2009
  8. pmc A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C
    Jules L Dienstag
    Gastrointestinal Unit, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
    Hepatology 54:396-405. 2011
  9. ncbi request reprint Lamivudine as initial treatment for chronic hepatitis B in the United States
    J L Dienstag
    Liver Biliary Pancreas Center, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston 02114, USA
    N Engl J Med 341:1256-63. 1999
  10. ncbi request reprint Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B
    Alexander Kuo
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetss 02114, USA
    Clin Gastroenterol Hepatol 2:266-72. 2004

Detail Information

Publications38

  1. ncbi request reprint Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy
    J L Dienstag
    Gastrointestinal Unit, Liver Biliary Pancreas Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Hepatology 30:1082-7. 1999
    ..Our observations suggest that lamivudine can be stopped after confirmed HBeAg loss or seroconversion...
  2. ncbi request reprint Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Drug Investig 27:35-49. 2007
    ....
  3. doi request reprint Hepatitis B virus infection
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital, and Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston 02114, USA
    N Engl J Med 359:1486-500. 2008
  4. ncbi request reprint Durability of serologic response after lamivudine treatment of chronic hepatitis B
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
    Hepatology 37:748-55. 2003
    ..Lamivudine retreatment for reappearance of hepatitis B markers can achieve resumption of viral suppression...
  5. ncbi request reprint Histological outcome during long-term lamivudine therapy
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital, Boston, MA 02114, USA
    Gastroenterology 124:105-17. 2003
    ..One year of lamivudine for chronic hepatitis B results in histologic improvement. We aimed to assess the histological impact of longer-term treatment...
  6. ncbi request reprint The role of liver biopsy in chronic hepatitis C
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital, Boston, MA 02114, USA
    Hepatology 36:S152-60. 2002
    ..Studies to identify noninvasive laboratory markers of histological activity and stage, especially genetic predictors of accelerated disease progression, command a high priority...
  7. doi request reprint Benefits and risks of nucleoside analog therapy for hepatitis B
    Jules L Dienstag
    Gastrointestinal Unit Medical Services, Massachusetts General Hospital and the Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston, MA 02114, USA
    Hepatology 49:S112-21. 2009
    ..Future studies are needed to develop drug regimens that are even more effective in achieving clinical endpoints, that are not hampered by resistance, and that are more confined in treatment duration but are more durable...
  8. pmc A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C
    Jules L Dienstag
    Gastrointestinal Unit, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
    Hepatology 54:396-405. 2011
    ..Baseline platelet count was a strong predictor of all clinical outcomes. During the 8 years of follow-up, death or liver transplantation occurred among 12.2% of patients with advanced fibrosis and 31.5% of those with cirrhosis...
  9. ncbi request reprint Lamivudine as initial treatment for chronic hepatitis B in the United States
    J L Dienstag
    Liver Biliary Pancreas Center, Massachusetts General Hospital, and the Department of Medicine, Harvard Medical School, Boston 02114, USA
    N Engl J Med 341:1256-63. 1999
    ..The primary end point with respect to efficacy was a reduction of at least 2 points in the score on the Histologic Activity Index. On this scale, scores can range from 0 (normal) to 22 (most severe abnormalities)...
  10. ncbi request reprint Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B
    Alexander Kuo
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetss 02114, USA
    Clin Gastroenterol Hepatol 2:266-72. 2004
    ..Tenofovir disoproxil fumarate is another nucleotide analogue with demonstrated antiviral activity against both wild-type and lamivudine-resistant HBV. Tenofovir, at its licensed dose, has not been associated with renal dysfunction...
  11. ncbi request reprint Looking to the future: new agents for chronic hepatitis B
    Jules L Dienstag
    Massachusetts General Hospital, Harvard Medical School, Blake 4, 55 Fruit Street, Boston, MA 02114, USA
    Am J Gastroenterol 101:S19-25. 2006
    ....
  12. pmc A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma
    Barham K Abu Dayyeh
    Gastrointestinal Unit, Massachusetts General Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114, USA
    Gastroenterology 141:141-9. 2011
    ..We tested associations between demographic, clinical, and genetic data and development of HCC, and developed a simple predictive model in a cohort of patients with chronic hepatitis C and advanced fibrosis...
  13. pmc Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis
    Kathleen E Corey
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 7:e27144. 2012
    ..Our data do not suggest any role for vitamin D supplementation in patients with advanced chronic hepatitis C and raise the possibility that higher vitamin D levels may be associated with disease progression...
  14. doi request reprint Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers
    Kathleen E Corey
    Harvard Medical School, Boston, MA, USA
    Infect Control Hosp Epidemiol 30:1000-5. 2009
    ..We sought to determine the safety, tolerability, and acceptance of postexposure prophylaxis with peginterferon alfa-2b in healthcare workers (HCWs) exposed to blood from HCV-infected patients...
  15. ncbi request reprint Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection
    Peter M Rosenberg
    Department of Pathology, Massachusetts General Hospital, Boston 02114, USA
    Am J Gastroenterol 97:478-83. 2002
    ..FCH may in part explain the accelerated development of cirrhosis previously observed among coinfected patients. Clinicians should remain vigilant for FCH in the HIV/HCV population and consider antiviral treatment in this setting...
  16. pmc The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort
    Barham K Abu Dayyeh
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Dig Dis Sci 56:564-8. 2011
    ..Both animal and limited human studies have shown that RAS inhibition with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor-1 [AT-1] blockers (ARBs) has antifibrogenic properties...
  17. ncbi request reprint American Gastroenterological Association technical review on the management of hepatitis C
    Jules L Dienstag
    Gastrointestinal Unit Medical Services Massachusetts General Hospital, Department of Medicine and Office of the Dean for Medical Education, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 130:231-64; quiz 214-7. 2006
  18. ncbi request reprint The value and limitations of long-term nucleoside antiviral therapy in chronic hepatitis B
    Jules L Dienstag
    J Hepatol 42:158-62. 2005
  19. ncbi request reprint Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 47:605-12. 2008
    ..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C...
  20. doi request reprint Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA
    Hepatology 47:789-98. 2008
    ..79). Multivariate analysis demonstrated that the serum fibrosis markers correlated substantially better with Ishak fibrosis scores than with the log hepatic collagen content (AUROC 0.84 versus 0.72)...
  21. pmc Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
    Hepatology 48:1412-9. 2008
    ..With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001)...
  22. ncbi request reprint Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders
    Eugene R Schiff
    Division of Hepatology, University of Miami, Jackson Medical Towers, 1500 N W 12th Avenue, Suite 1101, Miami, FL 33136, USA
    J Hepatol 38:818-26. 2003
    ..We assessed lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had failed interferon therapy previously...
  23. ncbi request reprint Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
    Robert P Perrillo
    Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Hepatology 36:186-94. 2002
    ..Asians and Caucasians had similar rates of response to lamivudine at comparable ALT levels...
  24. ncbi request reprint Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin
    John G McHutchison
    Division of Gastroenterology Hepatology, Scripps Clinic and Research Foundation, 10666 N Torrey Pines Road N203, La Jolla, CA 92037, USA
    Hepatology 35:688-93. 2002
    ..In conclusion, measurement of hepatic HCV RNA before or after therapy reflects changes observed in serum HCV RNA, and correlates inversely with hepatic inflammation and fibrosis, but otherwise has minimal clinical use...
  25. ncbi request reprint Oral antivirals for chronic hepatitis B
    Albert D Min
    Division of Digestive Diseases, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA
    Clin Liver Dis 11:851-68, ix. 2007
    ....
  26. ncbi request reprint Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
    ..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
  27. pmc Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis
    Herbert L Bonkovsky
    Liver Biliary Pancreatic Center and the Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA
    J Hepatol 46:420-31. 2007
    ..This study assessed HRQOL and sexual health in patients with advanced fibrosis or cirrhosis in the HALT-C Trial...
  28. ncbi request reprint Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
    Hepatology 42:282-92. 2005
    ..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
  29. ncbi request reprint Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  30. ncbi request reprint HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
    Hepatology 44:360-7. 2006
    ..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
  31. ncbi request reprint Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Hepatology 44:1675-84. 2006
    ..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
  32. ncbi request reprint Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, 48109 0362, USA
    Gastroenterology 125:1714-22. 2003
    ..The aim of this analysis was to determine the incidence of hepatitis flares, hepatic decompensation, and liver-disease-related (LDR) serious adverse events (SAE) during long-term lamivudine treatment...
  33. doi request reprint Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
    ..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
  34. ncbi request reprint Hepatitis C: a bitter harvest
    Jules L Dienstag
    Ann Intern Med 144:770-1. 2006
  35. ncbi request reprint Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
    William M Lee
    Control Clin Trials 25:472-92. 2004
    ..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity...
  36. ncbi request reprint American Gastroenterological Association medical position statement on the management of hepatitis C
    Jules L Dienstag
    Gastroenterology 130:225-30. 2006
  37. ncbi request reprint Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
    J Hepatol 43:434-41. 2005
    ..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy...
  38. ncbi request reprint Advancing patient care: integrating new data
    Teresa L Wright
    University of California San Francisco, and VA Medical Center 111B, San Francisco, CA 94121, USA
    Am J Gastroenterol 101:S32-9. 2006
    ..A number of issues were identified, and statements concerning possible management strategies that could be applied were developed...